Yijing Capital
Yijing Capital is an investment company established in 2015 and headquartered in Shanghai, China, with regional offices in Beijing, Hong Kong, Singapore, and Sydney. As a sister company of Yizhou Group, which ranks among China's Top 500 companies, Yijing Capital leverages decades of experience across various industries. The firm primarily focuses on the medical and health-care sector, as well as smart manufacturing, and aims to identify opportunities in high-growth industries. Yijing Capital operates multiple investment platforms and engages in equity investments using both proprietary and externally sourced funds. The company's core team possesses extensive operational and managerial expertise, enabling them to undertake a diverse range of investment projects both domestically and internationally, including sectors such as artificial intelligence, new retail, education, and new energy. Yijing Capital has successfully completed numerous investments, with several portfolio companies achieving significant growth and some going public, while also realizing substantial returns from strategic exits.
35 past transactions
Vertaxi
Series B in 2024
Vertaxi which develops and manufactures electric vertical takeoff and landing (eVTOL) aircraft.
Phomera
Series A in 2024
Phomera is a high-tech enterprise focused on the research and development, as well as the industrialization, of photonic crystal metamaterials. The company specializes in manufacturing flexible metamaterials that possess unique functionalities, including sound tuning, electrical conductivity, magnetic control, and color changing. Phomera is dedicated to delivering industry-specific solutions through inverse calculation and structural design, catering to diverse applications such as anti-counterfeiting, sensing, indication, protection, identification, and camouflage. Through its innovative approach, Phomera aims to advance technology in various sectors, providing tailored solutions to meet the needs of its customers.
Arnatar Therapeutics
Series A in 2024
Arnatar Therapeutics is a biopharmaceutical company that specializes in the development of novel nucleic acid medications.
Kangpu Biopharmaceuticals
Series B in 2023
Kangpu Biopharmaceuticals is a clinical-stage company dedicated to developing innovative small molecule drugs targeting immuno-modulating sites for treating cancer, autoimmune diseases, and inflammation. The company's proprietary technologies enable it to generate and degrade ubiquitin-protein, while its X-Synergy® drug discovery platform facilitates the development of novel therapies. Kangpu aims to improve patients' health conditions efficiently through its targeted protein ubiquitination and degradation solutions.
Taichu Biotechnology
Series A in 2023
Taichu Biotechnology is a biopharmaceutical company that specializes in providing customized Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) services. The company operates across the entire industry chain, focusing on drug non-clinical research and development, as well as the production of novel pharmaceuticals. Taichu's offerings encompass non-clinical drugability evaluations, antibody drug development, and the research and development of chemical preparations. By delivering tailored technical services for both individual and combined business sectors, Taichu Biotechnology supports the research and development, as well as the manufacturing processes, involved in creating a variety of new drugs.
NowYonMedical
Venture Round in 2023
NowYonMedical specializes in the production of medical device products. It also offers technical consulting, health management, and technology research in the field of life sciences.
Bivision
Seed Round in 2022
Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
Tasogare
Series C in 2022
Tasogare Coffee is a premium coffee brand located in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, ensuring accessibility for its customers. With a commitment to quality, Tasogare Coffee aims to deliver an exceptional coffee experience, appealing to discerning coffee enthusiasts.
Zhongguancun Shuimu Medical Technology
Series A in 2022
Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.
Leisen Electronic Technology
Venture Round in 2022
Leisen performs R&D of industry-leading radar technologies and products for solid protection for the safety of urban low airspace.
CytoNiche
Series B in 2022
CytoNiche specializes in 3D micro-structure engineering technology for stem cell research, translating Tsinghua University’s foundational research into commercial applications. The company develops 3D cell tissue engineering for high-quality stem cell cultures, injectable 3D micro-tissue therapies, and 3D drug screening microcarriers used in extensive drug screening operations. It provides reliable 3D micro-tissue products and services to research institutes, clinical institutions, stem cell companies, and drug discovery enterprises.
InnoStar Semiconductor
Series A in 2022
InnoStar Semiconductor is a developer and provider of advanced semiconductor storage technology, specializing in resistive random access memory (ReRam) chips. The company focuses on creating high-performance, low-power storage solutions tailored for applications in information security, Internet of Things (IoT), artificial intelligence (AI), and cloud computing. By commercializing its innovative ReRam technology, InnoStar aims to redefine storage capabilities and intelligent computing, enabling businesses to enhance security measures and meet the growing demands for efficient data storage and processing. Through its commitment to technological advancement, InnoStar Semiconductor is poised to set industry benchmarks in the semiconductor sector.
Xgene Pharmaceutical
Series C in 2021
Xgene Pharmaceutical Inc. is a pharmaceutical company founded in 2015 and based in the Cayman Islands. It focuses on developing small-molecule drugs aimed at treating chronic pain, infectious diseases, and tumors, with a particular emphasis on neurological disorders. As a late-clinical stage, venture-backed firm, Xgene utilizes proprietary linker technology to create novel, multimodal conjugated molecules. Its current programs are designed to enhance the efficacy and tolerability of pain medications, addressing unmet needs in the treatment of chronic pain and neurological conditions.
Walnut Computer Technology
Series A in 2021
Walnut Computer Technologies develops, markets, and provides associated services for medical software and hardware. They serve software that manages medical data, medical records, and medical imaging data by utilizing cloud computing technology, enabling medical institutions.
ChosenMed
Series C in 2021
ChosenMed is a healthcare company specializing in oncology precision medicine, primarily concentrating on early tumor screening and companion diagnosis. The company develops innovative oncology products aimed at the early detection, prevention, and diagnosis of tumors. ChosenMed emphasizes the guidance of targeted medication for solid tumors and the prediction of the efficacy of tumor immunotherapy. By offering a comprehensive suite of precision medical and immunotherapy solutions, the company seeks to enhance patient outcomes in the field of oncology.
Immunophage Biotech
Series A in 2021
Immunophage Biotech, established in 2016, is a Chinese pharmaceutical company dedicated to new drug development. Based in Nanjing, with its R&D center in Shanghai's Pujiang High-Tech Park, the company focuses on creating first-in-class immune-regulating therapies for cancer, autoimmune diseases, and neurodegenerative disorders.
Yizhun Intelligent
Series C in 2021
Yizhun AI is an artificial intelligence and robotics company focused on developing advanced medical imaging technology. Its primary objective is to enhance the detection of nodules and tumors in the lungs and mammary glands. By leveraging artificial intelligence, Yizhun AI's technology significantly accelerates the identification of malignant entities, thereby assisting healthcare professionals in making accurate diagnoses. Through its innovative solutions, the company aims to improve patient outcomes and streamline the diagnostic process in the medical field.
Kangpu Biopharmaceuticals
Series B in 2021
Kangpu Biopharmaceuticals is a clinical-stage company dedicated to developing innovative small molecule drugs targeting immuno-modulating sites for treating cancer, autoimmune diseases, and inflammation. The company's proprietary technologies enable it to generate and degrade ubiquitin-protein, while its X-Synergy® drug discovery platform facilitates the development of novel therapies. Kangpu aims to improve patients' health conditions efficiently through its targeted protein ubiquitination and degradation solutions.
Tasogare
Series B in 2021
Tasogare Coffee is a premium coffee brand located in Japan that specializes in producing and supplying a diverse range of coffee products. The company operates through both online and retail channels, ensuring accessibility for its customers. With a commitment to quality, Tasogare Coffee aims to deliver an exceptional coffee experience, appealing to discerning coffee enthusiasts.
Biren Technology
Series B in 2021
Biren Technology is a high-tech startup specializing in the design and development of intelligent processors tailored for GPU and DSA computation architectures. The company focuses on creating integrated software and hardware platforms that support intelligent computing applications, including cloud computing, artificial intelligence training, graphics rendering, and high-performance general-purpose computing. With a dedicated team of industry experts and elite engineers, Biren Technology aims to deliver versatile computing solutions that blend general computing capabilities with specific applications. Its research division is committed to advancing key technologies in intelligent computing systems, emphasizing new architectures and advanced compilation techniques, thereby facilitating technological breakthroughs in various high-tech sectors.
Artivila Therapeutics
Seed Round in 2021
Artivila Therapeutics is a pharmaceutical company based in Shenzhen, China, founded in 2018. It specializes in the research and development of new drugs, focusing on therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. The company leverages an AI-powered drug discovery engine to create an innovative platform that enables the consistent and efficient development of first-in-class molecules. Artivila Therapeutics aims to enhance patients' lives through advanced biotechnology and targeted therapeutics.
Keythera Pharmaceuticals
Series A in 2021
Keythera Pharmaceuticals is focused on the development of small molecule drugs aimed at addressing unmet medical needs, particularly in the treatment of tumors and autoimmune diseases. The company engages in the research and development of innovative therapeutics, utilizing advanced biomedical platforms to create novel medications. By prioritizing the discovery of effective treatments, Keythera aims to improve patient outcomes both in China and globally.
OriCell Therapeutics
Series A in 2021
OriCell Therapeutics is a biopharmaceutical company that specializes in the development of innovative cellular drugs aimed at addressing unmet clinical needs in tumor immunotherapy. The company focuses on creating therapeutics for a range of cancers, including liver cancer, myeloma, ovarian cancer, gastric cancer, cervical cancer, and non-small cell lung cancer. With a commitment to effective and affordable treatment options, OriCell Therapeutics aims to enhance patient care through the development of clinically valuable therapies, seeking to establish itself as a leader in the field of novel oncological treatments.
Raynovent
Series B in 2020
Raynovent is an innovative biotech company focused on researching and developing new drugs for liver and respiratory diseases. The company aims to create effective treatment therapies for patients suffering from viral and infectious illnesses in these areas. Through its expertise in pharmaceutical biotechnology consulting and technology transfer, Raynovent supports healthcare professionals in diagnosing and treating infectious diseases more effectively.
Zhiketong Technology
Series D in 2020
Beijing Zhiketong Technology Co., Ltd., established in 2014, specializes in providing direct marketing services for the hospitality, leisure, and entertainment sectors through its web platform on WeChat. The company acts as an agency that offers a range of digital marketing solutions, including consulting, advertising, and comprehensive data analysis. By assisting partners in optimizing their management efficiency and enhancing service quality, Zhiketong Technology helps businesses increase brand awareness and attract more customers. Its services encompass intelligent data analysis systems, online marketing strategies, customer management tools, and online store design, all aimed at driving revenue growth for hotels and tourism attractions in China.
Leto Laboratories
Series B in 2020
Leto Laboratories develops and researches advanced protein re‑engineering platforms to create novel therapeutic proteins. The company focuses on high‑throughput protein re‑screening, purification, fixed‑point coupling design, and formulation development to accelerate the creation of effective protein‑based drugs for cancer and rare disease patients.
etherna immunotherapies
Series B in 2020
eTheRNA Immunotherapies NV is a Belgium-based biotechnology company that specializes in the development of mRNA-based immunotherapies. Founded in 2013 and located in Niel, the company focuses on harnessing the immune system's dendritic cells to create treatments for melanoma, triple-negative breast cancer, and infectious diseases. eTheRNA has developed innovative TriMix technology that enhances the immune response, enabling patients to better combat these diseases. The company aims to be a leader in nucleic acid-based medicines, collaborating with partners to facilitate the creation of new drugs and improve patient outcomes. Additionally, eTheRNA has established a strategic partnership with China Grand Pharmaceutical and Healthcare Holdings Limited to further its mission.
independence Day
Series B in 2019
Independence Day is an internet platform that matches companies' needs with available spare time to provide employment services. In order to address businesses' temporary employment needs, they offer jobs to blue-collar workers and college students. It is a service platform that is offline.
Yidebang
Series B in 2019
Yidebang is a Beijing-based healthcare software developer, which provides management solution, drug supply, hierarchical diagnosis and treatment and other supporting medical services for basic-level clinics in China.
EO Company
Series C in 2019
EO Company is a technology and industry innovation service platform specializing in the large health sector. It offers a range of core services, including health technology media, industry business conferences, and research consultation. Targeting businesses within the big health industry, EO Company provides high-quality online products such as industry content planning, video columns, and consulting services. The platform emphasizes connecting key players across the industry chain, focusing on high market attention and an international perspective. Overall, EO Company plays a pivotal role in promoting technological advancement and innovation in the health sector.
Shanutec
Series B in 2018
Shanutec is a developer of smart household equipment and applications, focusing on the creation of integrated smart home systems. The company designs and manufactures a range of products, including electrical wiring solutions, power tracks, removable electric sockets, and various management systems for energy and environmental control. By providing safety systems and innovative household appliances, Shanutec enables homeowners to enhance their living environments with smart technology, ultimately aiming to improve comfort and convenience in domestic settings.
EO Company
Series B in 2018
EO Company is a technology and industry innovation service platform specializing in the large health sector. It offers a range of core services, including health technology media, industry business conferences, and research consultation. Targeting businesses within the big health industry, EO Company provides high-quality online products such as industry content planning, video columns, and consulting services. The platform emphasizes connecting key players across the industry chain, focusing on high market attention and an international perspective. Overall, EO Company plays a pivotal role in promoting technological advancement and innovation in the health sector.
Veritas Genetics
Venture Round in 2018
Veritas Genetics International Ltd. is a genetic testing service provider based in Danvers, Massachusetts, with operations across North America, Asia, and Europe. The company collaborates with scientists, physicians, advisors, and patient advocates to develop and deliver innovative genetic testing solutions. Veritas Genetics utilizes advanced genetic technology that can identify a broader spectrum of gene variations than conventional next-generation sequencing methods. Among its offerings, the company provides a screening test for hereditary breast and ovarian cancer risk, facilitating informed decision-making for clinical researchers and healthcare providers. Through its services, Veritas Genetics aims to empower individuals to lead healthier and longer lives.
EO Company
Series B in 2017
EO Company is a technology and industry innovation service platform specializing in the large health sector. It offers a range of core services, including health technology media, industry business conferences, and research consultation. Targeting businesses within the big health industry, EO Company provides high-quality online products such as industry content planning, video columns, and consulting services. The platform emphasizes connecting key players across the industry chain, focusing on high market attention and an international perspective. Overall, EO Company plays a pivotal role in promoting technological advancement and innovation in the health sector.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.